EUVIMEDEUVIMED entdecken
Crossref

Dual Targeting of m 7 G tRNA Modification and Histone Acetylation using Carrier‐Free Nano‐Epidrugs to Evoke Osteosarcoma Chemosensitization

Lin Qi iD, Wenchao Zhang iD, Changrong Shi, Chengyao Feng, Zhongyue Liu, Zhihong Li iD, Fang Fang iD, Xiaoyuan Chen iD

Advanced Materials · 2026-01 · 38 (4)

DOI: 10.1002/adma.202505951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 10.10.2025. Verfasst von Lin Qi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. Hauptthemen laut MEDLINE: Osteosarcoma, Histones, RNA, Transfer, Nanoparticles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: First Young Elite Scientists Sponsorship Program by CAST (Doctoral Student Special Program), Hunan Province Science and Technology Talent Support Project, National University of Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma has witnessed stagnant clinical outcomes over the past four decades, owing to the inevitable reduction in chemosensitivity during treatment. Although epigenetics offers promising strategies to augment chemosensitivity, its role in osteosarcoma remains elusive. Here, by analyzing clinical cohorts, it is found that the aberrant overexpression of methyltransferase 1 (METTL1), a key N 7 ‐methylguanosine (m 7 G) modulator, and histone deacetylase 1 (HDAC1), associated with poor chemotherapeutic response in osteosarcoma. To target these epigenetic vulnerabilities, innovative carrier‐free nano‐epidrugs (siMBD‐R NPs) are developed, incorporating first‐line doxorubicin (DOX) with siRNA against METTL1 (siMETTL1), FDA‐approved HDAC inhibitor belinostat (BEL), and DSPE‐PEG 2000 ‐cRGD. With ultrahigh active pharmaceutical ingredient (API) loading content (≈92.7 wt.%), tumor‐specific targeting capability, and unique pH‐responsive release characteristics, the siMBD‐R NPs indicate remarkable tumor accumulation (15.2‐fold enhancement) compared to free siMETTL1. Importantly, through dual‐epigenetic regulation, the nano‐epidrugs markedly amplify DOX‐triggered DNA damage. Specifically, siMETTL1 selectively disrupts m 7 G‐modified tRNA‐mediated translation of DNA repair proteins, and BEL‐induced HDAC inhibition remodels chromatin into a more accessible state, promoting DNA damage accumulation. In vivo studies demonstrate that siMBD‐R NPs can significantly potentiate chemosensitivity, achieving an 81.5% relative increase in tumor inhibition, and can activate an immune response. This work highlights the potential benefits of leveraging dual‐targeted epigenetic intervention to evoke osteosarcoma chemosensitization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaHistonesRNA, TransferNanoparticlesAntineoplastic AgentsBone NeoplasmsHumansAnimalsCell Line, TumorDoxorubicinAcetylationMiceMethyltransferasesHistone Deacetylase InhibitorsRNA, Small InterferingDrug CarriersHistone Deacetylase 1

Stichwörter der Autor:innen

N7‐methylguanosinecarrier‐free nanodrugschemotherapydoxorubicinepigenetic regulationhistone deacetylationosteosarcoma

Substanzen

HistonesDoxorubicinRNA, TransferMethyltransferasesAntineoplastic AgentsHistone Deacetylase InhibitorsRNA, Small InterferingDrug CarriersHistone Deacetylase 1

Autor:innen und Institutionen

  • Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, Hunan, 410011, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
  • Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575, Singapore.

ORCID-Profile: Lin Qi, Wenchao Zhang, Zhihong Li, Fang Fang, Xiaoyuan Chen

Förderung

  • First Young Elite Scientists Sponsorship Program by CAST (Doctoral Student Special Program)
  • Hunan Province Science and Technology Talent Support Project
  • National University of Singapore
  • National Medical Research Council
  • National Research Foundation
  • Ministry of Education - Singapore
  • Agency for Science, Technology and Research (A*STAR)
  • NUS-Nanjing University Research Collaboration Fund 2025 Award

Zitieren

APA

Qi, L., Zhang, W., Shi, C., Feng, C., Liu, Z., Li, Z., Fang, F., & Chen, X. (2026). Dual Targeting of m 7 G tRNA Modification and Histone Acetylation using Carrier‐Free Nano‐Epidrugs to Evoke Osteosarcoma Chemosensitization. Advanced Materials, 38(4). https://doi.org/10.1002/adma.202505951

Vancouver

Qi L, Zhang W, Shi C, Feng C, Liu Z, Li Z, et al. Dual Targeting of m 7 G tRNA Modification and Histone Acetylation using Carrier‐Free Nano‐Epidrugs to Evoke Osteosarcoma Chemosensitization. Advanced Materials. 2026;38(4). doi:10.1002/adma.202505951

BibTeX
@article{Qi2026,
  author = {Qi, Lin and Zhang, Wenchao and Shi, Changrong and Feng, Chengyao and Liu, Zhongyue and Li, Zhihong and Fang, Fang and Chen, Xiaoyuan},
  title = {Dual Targeting of m 7 G tRNA Modification and Histone Acetylation using Carrier‐Free Nano‐Epidrugs to Evoke Osteosarcoma Chemosensitization},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {4},
  doi = {10.1002/adma.202505951}
}
Kostenlos starten →